$0.82 -0.0 -3.9%
Last Trade - 25/02/21
| Market Cap | £138.8m |
| Enterprise Value | £87.7m |
| Revenue | £-320k |
| Position in Universe | 4447th / 6713 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 30th Jun | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 13.0 | 0.000 | 44.7 | 67.1 | 60.3 | 0.12 | 1.90 | 15.9 | -60.9% | ||
| +40.9 | ||||||||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Palatin Technologies, Inc. (Palatin) is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The Company’s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. The melanocortin receptor (MCr) system is hormone driven, with effects on food intake, metabolism, sexual function, inflammation and immune system responses. There are five melanocortin receptors, MC1r through MC5r. The natriuretic peptide receptor (NPR) system regulates cardiovascular functions, and therapeutic agents modulating this system have potential to treat fibrotic diseases, cardiovascular diseases, including reducing cardiac hypertrophy and fibrosis, heart failure, acute asthma, pulmonary diseases and hypertension.
| Last Annual | June 30th, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | November 21, 1986 |
| Public Since | December 21, 1999 |
| No. of Shareholders: | 106 |
| No. of Employees: | 20 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | |
| Exchange | NYSE MKT |
| Shares in Issue | 230,034,307 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 4B Cedarbrook Dr, CRANBURY, 08512-3641, United States |
| Web | https://www.palatin.com/ |
| Phone | +1 609 4952200 |
| Contact | () |
| Auditors | KPMG LLP |
As of 25/02/21, shares in Palatin Technologies Inc are trading at $0.82, giving the company a market capitalisation of £138.8m. This share price information is delayed by 15 minutes.
Shares in Palatin Technologies Inc are currently trading at $0.82 and the price has moved by 53.34% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Palatin Technologies Inc price has moved by 23.12% over the past year.
Of the analysts with advisory recommendations for Palatin Technologies Inc, there are there are currently 2 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Palatin Technologies Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Palatin Technologies Inc is scheduled to issue upcoming financial results on the following dates:
Palatin Technologies Inc does not currently pay a dividend.
Palatin Technologies Inc does not currently pay a dividend.
Palatin Technologies Inc does not currently pay a dividend.
To buy shares in Palatin Technologies Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Palatin Technologies Inc are currently trading at $0.82, giving the company a market capitalisation of £138.8m.
Here are the trading details for Palatin Technologies Inc:
Based on an overall assessment of its quality, value and momentum, Palatin Technologies Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Palatin Technologies Inc are currently priced at $0.82. At that level they are trading at 0.173% discount to the analyst consensus target price of 0.00.
Analysts covering Palatin Technologies Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.137 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Palatin Technologies Inc. Over the past six months, the relative strength of its shares against the market has been 42.44%. At the current price of $0.82, shares in Palatin Technologies Inc are trading at 47.13% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Palatin Technologies Inc.
Palatin Technologies Inc's management team is headed by:
Here are the top five shareholders of Palatin Technologies Inc based on the size of their shareholding:
